MONISTAT 7 (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1974.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
MONISTAT 7 (miconazole nitrate) is a vaginal antifungal cream indicated for vulvovaginal candidiasis. The drug exhibits fungicidal activity against Candida species, with minimal systemic absorption following intravaginal administration. Miconazole nitrate demonstrates clinical efficacy comparable to shorter-duration formulations, establishing it as a standard-of-care option for vaginal yeast infections.
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals declining brand team headcount and shift toward generic/OTC optimization roles.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 7 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MONISTAT 7 offers stability in a mature franchise but limited career acceleration potential. The approaching LOE and low linked job count suggest the brand team is lean, with focus on defending market share against generics and OTC competitors rather than growth initiatives.